AGN-192403 hydrochloride | CAS# 1021868-90-5 | Biochemical

MedKoo Cat#: 573479 | Name: AGN-192403 hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AGN-192403 hydrochloride is the hydrochloride salt of AGN 192403 --- a known midazoline drug with high affinity for the imidazoline I1 receptor. AGN-192403 may affect oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes.

Chemical Structure

AGN-192403 hydrochloride

CAS#1021868-90-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 573479

Name: AGN-192403 hydrochloride

CAS#: 1021868-90-5 (HCl)

Chemical Formula: C10H20ClN

Exact Mass: 189.1284

Molecular Weight: 189.73

Elemental Analysis: C, 63.31; H, 10.63; Cl, 18.68; N, 7.38

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks
25mg	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

175521-95-6 (free base) 1021868-90-5 (HCl)

Synonym

AGN-192403 hydrochloride, AGN192403 hydrochloride, AGN 192403 hydrochloride, AGN-192403 HCl

IUPAC/Chemical Name

(+/-)-2-endo-Amino-3-exo-isopropylbicyclo(2.2.1)heptane hydrochloride

InChi Key

KSTGYMXUFHCTSM-MRUBQFBLSA-N

InChi Code

1S/C10H19N.ClH/c1-6(2)9-7-3-4-8(5-7)10(9)11;/h6-10H,3-5,11H2,1-2H3;1H/t7-,8+,9+,10+;/m1./s1

SMILES Code

Cl.CC(C)[C@H]1[C@@H]2CC[C@@H](C2)[C@@H]1N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 189.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Choi DH, Kim DH, Park YG, Chun BG, Choi SH. Protective effects of rilmenidine and AGN 192403 on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. Free Radic Biol Med. 2002 Nov 15;33(10):1321-33. doi: 10.1016/s0891-5849(02)01041-9. PMID: 12419464. 2: Chamberlain BT, Vincent M, Nafie J, Müller P, Greka A, Wagner FF. Multigram Preparation of BRD4780 Enantiomers and Assignment of Absolute Stereochemistry. J Org Chem. 2021 Mar 5;86(5):4281-4289. doi: 10.1021/acs.joc.0c02520. Epub 2021 Feb 22. PMID: 33618515. 3: Cobos-Puc LE, Aguayo-Morales H, Silva-Belmares Y, González-Zavala MA, Centurión D. α2A-adrenoceptors, but not nitric oxide, mediate the peripheral cardiac sympatho-inhibition of moxonidine. Eur J Pharmacol. 2016 Jul 5;782:35-43. doi: 10.1016/j.ejphar.2016.04.043. Epub 2016 Apr 22. PMID: 27112661. 4: Zádori ZS, Fehér Á, Al-Khrasani M, Lackó E, Tóth VE, Brancati SB, Hein L, Mátyus P, Gyires K. Imidazoline versus alpha₂-adrenoceptors in the control of gastric motility in mice. Eur J Pharmacol. 2013 Apr 5;705(1-3):61-7. doi: 10.1016/j.ejphar.2013.02.043. Epub 2013 Mar 13. PMID: 23499689. 5: Cobos-Puc L, Aguayo-Morales H, Ventura-Sobrevilla J, Luque-Contreras D, Chin- Chan M. Further analysis of the inhibition by agmatine on the cardiac sympathetic outflow: Role of the α2-adrenoceptor subtypes. Eur J Pharmacol. 2017 Jun 15;805:75-83. doi: 10.1016/j.ejphar.2017.03.009. Epub 2017 Mar 14. PMID: 28315344. 6: Cobos-Puc LE, Sánchez-López A, Centurión D. Pharmacological analysis of the cardiac sympatho-inhibitory actions of moxonidine and agmatine in pithed spontaneously hypertensive rats. Eur J Pharmacol. 2016 Nov 15;791:25-36. doi: 10.1016/j.ejphar.2016.08.017. Epub 2016 Aug 24. PMID: 27565220. 7: Yu Y, Koss MC. Rat clonidine mydriasis model: imidazoline receptors are not involved. Auton Neurosci. 2005 Jan 15;117(1):17-24. doi: 10.1016/j.autneu.2004.10.001. PMID: 15620566. 8: Rubio-Beltrán E, Labastida-Ramírez A, Hernández-Abreu O, MaassenVanDenBrink A, Villalón CM. Pharmacological analysis of the inhibition produced by moxonidine and agmatine on the vasodepressor sensory CGRPergic outflow in pithed rats. Eur J Pharmacol. 2017 Oct 5;812:97-103. doi: 10.1016/j.ejphar.2017.07.020. Epub 2017 Jul 8. PMID: 28694067. 9: Yang J, Sun N, Xiong Q, Yang R. Effect of moxonidine on the uveoscleral outflow: role of alpha2-adrenoceptors or i1 imidazoline receptors. Curr Eye Res. 2009 Apr;34(4):287-96. doi: 10.1080/02713680902750077. PMID: 19373577. 10: Fehér Á, Tóth VE, Al-Khrasani M, Balogh M, Lázár B, Helyes Z, Gyires K, Zádori ZS. Analysing the effect of I1 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology. 2017 Feb;25(1):107-118. doi: 10.1007/s10787-016-0299-7. Epub 2016 Nov 21. PMID: 27873165. 11: Zhou X, He D, Yan X, Chen X, Li R, Zhang G, Wang J. Moxonidine inhibits excitatory inputs to airway vagal preganglionic neurons via activation of both α2-adrenoceptors and imidazoline I1 receptors. Brain Res. 2020 Apr 1;1732:146695. doi: 10.1016/j.brainres.2020.146695. Epub 2020 Jan 31. PMID: 32007398. 12: Hayar A, Guyenet PG. Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL. J Neurophysiol. 2000 Feb;83(2):766-76. doi: 10.1152/jn.2000.83.2.766. PMID: 10669492. 13: Velliquette RA, Ernsberger P. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther. 2003 Aug;306(2):646-57. doi: 10.1124/jpet.103.050468. Epub 2003 May 19. PMID: 12756274. 14: Chao HM, Osborne NN. Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors. Brain Res. 2001 Jun 15;904(1):126-36. doi: 10.1016/s0006-8993(01)02499-4. PMID: 11516418. 15: Zádori ZS, Tóth VE, Fehér Á, Philipp K, Németh J, Gyires K. Evidence for the gastric cytoprotective effect of centrally injected agmatine. Brain Res Bull. 2014 Sep;108:51-9. doi: 10.1016/j.brainresbull.2014.07.008. Epub 2014 Aug 27. PMID: 25171957. 16: Sastre-Coll A, Esteban S, García-Sevilla JA. Effects of imidazoline receptor ligands on monoamine synthesis in the rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jul;360(1):50-62. doi: 10.1007/s002109900032. PMID: 10463334. 17: Raasch W, Jungbluth B, Schäfer U, Häuser W, Dominiak P. Norepinephrine release is reduced by I(1)-receptors in addition to alpha(2)-adrenoceptors. Ann N Y Acad Sci. 2003 Dec;1009:270-3. doi: 10.1196/annals.1304.034. PMID: 15028598. 18: Schäfer U, Burgdorf C, Engelhardt A, Raasch W, Kurz T, Richardt G. Moxonidine displays a presynaptic alpha-2-adrenoceptor-dependent synergistic sympathoinhibitory action at imidazoline-1 receptors. Ann N Y Acad Sci. 2003 Dec;1009:265-9. doi: 10.1196/annals.1304.033. PMID: 15028597. 19: Mukaddam-Daher S, Menaouar A, Gutkowska J. Receptors involved in moxonidine- stimulated atrial natriuretic peptide release from isolated normotensive rat hearts. Eur J Pharmacol. 2006 Jul 10;541(1-2):73-9. doi: 10.1016/j.ejphar.2006.05.009. Epub 2006 May 12. PMID: 16774751. 20: Cobos-Puc LE, Villalón CM, Ramírez-Rosas MB, Sánchez-López A, Lozano-Cuenca J, Gómez-Díaz B, MaassenVanDenBrink A, Centurión D. Pharmacological characterization of the inhibition by moxonidine and agmatine on the cardioaccelerator sympathetic outflow in pithed rats. Eur J Pharmacol. 2009 Aug 15;616(1-3):175-82. doi: 10.1016/j.ejphar.2009.06.003. Epub 2009 Jun 13. PMID: 19527708.